*Images are for illustrative purposes only

Marbonor 100mg/ml Solution for Injection for Cattle and Pigs


Marbonor Injection is an antimicrobial solution for injection containing marbofloxacin. It is indicated for the treatment of respiratory infections and acute mastitis in cattle and the treatment of metritis mastitis agalactia syndrome (postpartum dy
Prescription Medicine
  • Select Option
  • 100ml
Browse other products from the Marbonor range
Clinical particulars
Target species
Cattle and Pigs (sows).
Indications for use, specifying the target species
Treatment of respiratory infections caused by susceptible strains of Pasteurella multocida, Mannheimia haemolytica and Mycoplasma bovis.
Treatment of acute mastitis caused by Escherichia coli strains susceptible to marbofloxacin during the lactation period.
Treatment of Metritis Mastitis Agalactia Syndrome (postpartum dysgalactia syndrome, PDS) caused by bacterial strains susceptible to marbofloxacin.
Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Special Warnings for each target species
The efficacy data showed that the product has insufficient efficacy for the treatment of acute forms of mastitis induced by Gram-positive bacteria.
Special precautions for use
Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based upon susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to (fluoro)quinolones should avoid any contact with the veterinary medicinal product.
If the product comes into contact with skin or eyes, rinse with copious amounts of water.
Do not drink, eat or smoke whilst using the veterinary medicinal product.
Wash hands after use.
Accidental self-injection can induce slight irritation.
In case of accidental self-injection or ingestion, seek medical advice immediately and show package leaflet or the label to the physician.
Adverse reactions (frequency and seriousness)
Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site and inflammatory lesions which may persist for at least 12 days after injection. However, in cattle the subcutaneous route was shown to be better tolerated locally than the intramuscular route. Therefore, the subcutaneous route is recommended in heavy cattle.
Use during pregnancy, lactation or lay
May be used in pregnant and lactating cows and sows.
Interaction with other medicinal products and other forms of interaction
None known.
Amounts to be administered and administration route
To ensure administration of a correct dose, bodyweight should be determined as accurately as possible to avoid underdosing.
The recommended dosage is 2 mg marbofloxacin/kg bodyweight (1 ml of the product/50 kg bodyweight) in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs. For the injections, the neck should be preferred in cattle and pigs.
Treatment durations are 3 days in pigs and 3 to 5 days in cattle.
The vial may be broached up to 35 times. The user should choose the most appropriate vial size according to the target species to be treated.
Overdose (symptoms, emergency procedures, antidotes), if necessary
No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively.
Signs such as neurological disorders may occur when the dose is exceeded.
Such signs should be treated symptomatically.
Withdrawal period(s)
Meat and offal: 6 days
Milk: 36 hours
Meat and offal: 4 days.
Pharmacological particulars
Pharmacotherapeutic Group: Antibacterials for systemic use, Flouroquinolones.
ATC Vet Code: QJ01MA93
Pharmacodynamic properties
Marbofloxacin is a synthetic, broad spectrum antimicrobial, belonging to the fluoroquinolone group of antibiotics. Marbofloxacin is bactericidal with efficacy against a wide range of Gram-negative bacteria, Gram-positive bacteria and Mycoplasma species. The mechanism of action of marbofloxacin is based on the inhibition of type II topoisomerases, DNA gyrase and topoisomerase IV.
A 6 year pan European study by Kroemer, S et al 2012, reviewed marbofloxacin efficacy against indicated pathogens isolated from cases of bovine respiratory disease. In this study, 751 isolates of P. multocida were identified, over 99% of which were determined to be highly susceptible to marbofloxacin with MIC ranging from 0.004 to 1µg/ml. MIC50 was identified as 0.015µg/ml and MIC90 was 0.120µg/ml. This study also assessed 514 isolates of M. haemolytica with >98% of isolates determined to be highly susceptible with a MIC range of 0.008 to 1µg/ml, MIC50 value of 0.03µg/ml and MIC90 value of 0.25µg/ml. 171 isolates of M. bovis were identified with 74% demonstrating susceptibility with MIC ranging from 0.5 to 1µg/ml, 25% exhibiting intermediate susceptibility with MIC of 2µg/ml and 1% demonstrating resistance with MIC of 4 µg/ml. MIC50 was 1µg/ml and MIC90 was 2µg/ml; however these were deemed to be irrelevant due to the low number of isolates. This study also reviewed marbofloxacin efficacy in E. coli mastitis which analysed 617 isolates and demonstrated over 98% susceptibility with MIC of these susceptible organisms ranging from 0.008 to 1µg/ml. MIC50 and MIC90 were both determined to be 0.03µg/ml. In a pan European study by El Garch et al 2017, 369 E. Coli isolates from porcine metritis identified 92.7% susceptibility to marbofloxacin with a MIC ranging from 0.008 to 1 µg/ml. 0.3% of isolates exhibited intermediate susceptibility with a MIC of 2 and 7% exhibited resistance with a MIC of >4. MIC50 was determined to be 0.03µg/ml and MIC90 was 0.5µg/ml.
The pan European studies by Kroemer, S et al 2012 and El Garch, F., et al 2017, established clinical breakpoints for marbofloxacin use in P. multocida and M. haemolytica associated bovine respiratory disease and E. Coli in bovine mastitis and porcine metritis. Resistant strains were determined to have a MIC of =4 µg/ml, intermediate strains a MIC=2 µg/ml and susceptible strains, a MIC=1 µg/ml. No clinical breakpoints have been established for Mycoplasma species.
Resistance to fluoroquinolones mainly occurs by chromosomal mutations with three mechanisms: decrease of the bacterial cell wall permeability, change in expression of efflux pump genes or mutation within genes coding for target enzymes. Plasmid mediated quinolone resistance is a separate mechanism by which resistance may develop. This may occur via three different mechanisms: through plasmid genes coding for proteins which protect DNA gyrase and topoisomerase IV from quinolone inhibition, through acetylation of certain quinolones by a variant of acetyltransferase AAC(6')-Ib or through plasmid genes coding for enhanced efflux pumps. Whilst the low-level resistance this confers should not exceed the clinical breakpoints for susceptibility, it may enable selection of higher level resistance.
Pharmacokinetic properties
After subcutaneous or intramuscular administration in cattle and pigs, at the recommended dose of 2 mg/kg bodyweight, marbofloxacin is readily absorbed and reaches peak plasma concentrations of 1.5 µg/ml within 1 hour. The bioavailability of marbofloxacin is almost 100%.
Marbofloxacin is weakly bound to plasma proteins (less than 10% in pigs and 30 % in cattle), extensively distributed and achieves a higher concentration in most tissues, (liver, kidney, skin, lung, bladder, uterus and digestive tract) than in plasma.
In cattle, marbofloxacin is eliminated slowly in pre-ruminant calves but faster in ruminant cattle (t1/2 = 5-9 hours and 4 – 7 hours respectively). In pre-ruminant calves elimination of the active form is predominantly via urine, (¾ urine, ¼ faeces). In ruminant cattle the active form is eliminated equally in urine and faeces.
In pigs, the active form of marbofloxacin is eliminated slowly (t1/2= 8 – 10 hours) predominantly via urine (2/3) and faeces (1/3).
Pharmaceutical particulars
List of excipients
Disodium Edetate
Water for injections
Major Incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years
Shelf-life after first opening the immediate packaging: 28 days
Special precautions for storage
Do not store above 25°C.
Protect from light.
Nature and composition of immediate packaging
The product is packaged in 20 ml, 50 ml, 100 ml 250 ml and 500 ml amber type II glass vials and 60 ml, 100 ml, 250 ml and 500 ml amber co-ex plastic (polypropylene) vials.
The vials are closed with chlorobutyl rubber stoppers sealed with aluminium caps.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Shipping charges mainland UK zone1

Value Weight Delivery Charge
Over £49.00 Any Weight FREE
Under £49.00 No weight limit £4.50
Under £49.00 Under 250g £2.99

Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited options are available.

NB: Orders placed with faster delivery must be placed before 13:00 to ensure same day dispatch (excluding weekends and bank holidays). Please also check on the product page that the items ordered show 'In Stock' otherwise your order will be delayed until the stock becomes available, which in most cases will only be 24hrs.

Estimated "Usually shipped in" information is shown against most products

Overseas orders

Postage outside of the UK is from £4.50

Prescription Items

Prescription items will be sent on receipt of a valid signed and dated prescription.

Pick up

We offer a pickup service for orders placed over the phone.

Please ring us on 01833 641112 for more information.

Refrigerated Items

Refrigerated items will be sent by carrier or Royal Mail with coolpacks unless you pay for a premium for a refrigerated delivery. We will contact you prior to despatch for your instructions.

We want you to be completely satisfied with any purchase. If not any item* can be returned to us within 14 days of receipt for exchange or refund Please give us a ring for a returns number on 01833 641112 or alternatively email sales@hyperdrug.co.uk to obtain a returns number.

*Due to legal requirements medicines may not be returned except to correct an error in despatch or in response to an "official recall". If an item is believed to be faulty it should be returned for inspection and it may be necessary to forward it to the manufacturers for testing before replacements or refunds can be authorised. This does not infringe legal rights. Please contact our customer services for a "Returns Number" which must appear on the outside of the package or it will not be accepted. We advise customers to use an insured method of shipping and to retain proof of despatch. We may refuse returns on products specially obtained or manufactured to order. Items must be returned unsoiled and unused and sent adequately packed and carriage paid.

Related Products